Fittingly, in ADAM17-silenced breast cancer cells, p-AKT levels are likewise significantly decreased [55], and forced expression of ADAM17 enhanced the phosphorylation of AKT in hepatocellular carcinoma cells without affecting the expression of total AKT [64]. This evidence concerns the gene ADAM17 and breast cancer.